INTRODUCTION
The most recent systematic review of interventions for the prevention of suicide 1 demonstrates a lack of evidence for the effectiveness for any additional psychosocial intervention following an act of self harm in preventing subsequent suicide. This comes eight years after a major review of interventions to prevent repetition of deliberate self harm reached similarly dispiriting conclusions. 2 Establishing an effective means of preventing suicide at the primary or secondary care level remains ill-defined despite pressures to reduce suicide rates further 3 and a climate where psychiatric services are increasingly judged by their performance in reaching these targets. In the absence of any clear benefit from the options evaluated to date, attempts have been made to fill the policy gap with short-term solutions, 4 consensus opinion 5 or fragmented guidance. 6, 7 Consequently local services remain patchy and poorly organized, a situation that is extremely discomforting given the size of the problem. 8 Crawford's team point out that despite suicide data on a population of 3918 subjects, their meta-analysis lacked statistical power, but also suggest that the weakness of the existing evidence highlights a need to concentrate future research on population-based strategies. Whilst certain public health policies have shown effectiveness, for example in limiting availability of means and media influences and in improving the detection and treatment of mental illness, 9 much research into strategies for high-risk groups has been hampered by the methodological problems outlined in this article. 10 If these difficulties could be surmounted, interventions in primary and secondary care might well emerge as effective strategies, finally allowing clinicians to practice evidence-based suicide prevention.
METHODOLOGICAL PROBLEMS IN SUICIDOLOGY
Most immediately striking as a methodological challenge is the fact that suicide is a rare outcome, requiring large trials in order to detect clinically significant reductions in the base rate. Behavioural characteristics of the study population exacerbate this problem by tending towards high attrition rates. Additional problems result from the often necessary use of multi-centre trials where effect sizes may be underestimated due to contamination in centres where there is little difference between 'treatment as usual' (TAU) and the intervention on trial. 11 A fourth area of difficulty is the diversity of the population at risk, the characteristics of which vary according to age, gender, ethnic group, diagnosis and behaviour. This group comprises individuals with overlapping diagnoses of depressive disorders, bipolar affective disorder, substance misuse problems, anxiety disorders, schizophrenia and different permutations of personality disorders and traits, or those with no diagnosis at all. The presence or absence of personality disorder is a strong predictor of the risk of self harm and its frequency, but regardless of diagnosis the interpersonal problems and intentions underlying every act of self harm are varied and extremely unpredictable. 12 This is particularly true where cultural factors come into play and in a society where the ethnic mix is evolving rapidly. Herein lies the crux of the problem: suicide and deliberate self harm are behaviours, not diagnoses, and have diverse underlying pathologies. With such a heterogeneous population at risk a goal of one treatment for all seems unrealistic, and policy-focused research design should ideally reflect this.
behaviour that have produced negative findings, 11, [13] [14] [15] [16] [17] [18] although clearly another explanation is that the interventions were simply ineffective. A small number of trials have shown positive findings, but such trials are often dismissed as being of limited generalizability. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Where syntheses of results by meta-analysis have attempted to further utilize these data sets there has been inadequate power to detect differences, and consequently calls have been made to conduct larger-scale trials of interventions shown to be of possible benefit in small trials. 1 Although this might provide adequate power, the research endeavour would only be of value if its study population shared similar characteristics to those shown to benefit from the intervention in smaller trials. When evaluated in a mixed population, any potential treatment effect could run the risk of becoming diluted or of differential treatment effects cancelling each other out, yielding yet more negative results.
Support for this idea comes from subgroup analysis of negative studies which reveal significant (or near-significant) reductions or indeed paradoxical increases in risk for specific groups following an intervention. 14, 18 The observation that certain treatment plans serve to positively reinforce self-harming behaviour is well recognized, particularly in patients with borderline personality disorder. 29 Evidence is also emerging that pharmacological treatments can increase risk in certain groups at key temporal stages in treatment. 30, 31 Within such a mixed patient population, differential responses to treatments are hardly surprising and suggest it is more prudent, more ethical and a more cost-effective use of research funds to focus on selected patient subgroups in the evaluation and implementation of interventions.
POTENTIAL SOLUTIONS
Future trials face the challenge of being able to generate adequate statistical power whilst maintaining tightly defined inclusion and exclusion criteria. Only by achieving this can researchers identify precisely which interventions are best suited to specific patient groups. In gradually building up a jigsaw of effective interventions matched to target groups, a series of clinical guidelines could emerge. Conceptually organized as a decision tree, and amenable to use in a system of stepped care, clinicians would be able to identify evidence-based interventions suited to the demographic, diagnostic and behavioural characteristics of each patient encountered (Figure 1) . A young female patient who has taken the fifth in a series of overdoses is likely to be offered an intervention very different to that identified as appropriate for a severely depressed male in his late 60s, with worsening osteoarthritis, who has never self-harmed. Where the evidence was available, guidelines could also include data on cost-effectiveness and acceptability, as well as alerts for any interventions causing increased risk for that subgroup.
At times suicidologists have exhorted researchers to 'think big' in establishing large-scale, long-term and rigorously constructed trials. 10 Given the intrinsic peculiarities of suicidality, however, this may be encouraging further cost-ineffective research unless rigid inclusion and exclusion criteria define a homogenous study population. Although this inevitably increases the operational costs of a study it also increases the likelihood of yielding results that can be translated into policy. Other advantages of this subgroup approach include the addressing of inequalities in Figure 1 Schematic representation of a decision tree used to match interventions to the demographic, diagnostic and behavioural characteristics of self-harming patients health by targeting effective interventions at marginalized groups, for example those with personality disorders or those newly released from prison, and the encouragement of research into interventions appropriate to refugees and ethnic minorities. This upholds one of the rights to health, namely universal access to good quality health care, by improving consistency of care and promoting distributive justice. 32 There are other ways of increasing the proportion of research information useful to policy makers in suicide prevention. Studies using outcome measures wider than data on completed suicides or acts of self harm are often easier to design and conduct (both ethically and methodologically) and can also help identify treatments that reduce risk factors for self harm. This is relevant both because any intervention shown to reduce suicidal ideation and behaviour may reasonably be thought to have an impact on reducing morbidity and preventing completed suicide, and because of the public health impact of deliberate self harm per se. Acts of self harm can be as costly as suicide in terms of loss of productive life and family disruption, but government targets do not reflect this. Intermediate outcomes such as reductions in scores of depression or hopelessness offer utility as proxy measures both in terms of study design and in their application to clinical settings. Treatments that have been demonstrated to reduce scores on scales of psychiatric morbidity could be applied to the management of patient groups at risk of self harm as well as to those who have actually self-harmed. 33 Even interventions that are shown to impact on more distal variables like quality of life or personality disorder severity scales may have a role in guiding management and promoting further research into their impact on repetition of deliberate self harm. 34 A broader choice of study type could increase the generalizability of findings, particularly given that randomized controlled trials, usually regarded as the gold standard in evidence-based research, may not always reflect clinical reality. Observational studies have often been a valuable complement to evidence amassed in randomized trials 35 and may have been under-utilized, especially given their suitability for rare conditions and exposures and their ethical superiority in certain situations. Finally, if costeffectiveness studies and patient acceptability measures were factored into all evaluations, decision-making could take into account the scarce resources allocated to mental health and acknowledge issues around treatment concordance. In the absence of demonstrated cost-effectiveness data, some would argue that a reliance on cost-minimization analysis or inferences made from cost-effectiveness acceptability curves is an adequate basis for justifying use of public funds, particularly when the cost of services for self harm are so great. 17 Although the policy ideal is to implement only those policies that are cost-effective, social values are also important, particularly when the tools of economic analysis can be quite blunt. 36 
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CONCLUSIONS
With such a heterogeneous population as the province for suicide prevention it is not surprising that individual interventions are likely to be differentially effective in defined subgroups. The goal of one treatment for all may be unrealistic and this has implications for current policy and for future research design. The research base for evidencebased policy in suicide prevention is likely to consist of a whole series of trials which manage to fulfil the oftenconflicting aims of concentrating on defined populations whilst also achieving adequate power (of at least n=250). Where effective interventions are identified these can be added to a series of guidelines linked to the specific patients predicted to show the most benefit. In clinical practice this series of guidelines might be presented as a decision tree, guiding clinicians towards the specific characteristics of their patient and any interventions matched to them. This incremental and comprehensive approach has the advantage of catering to the diversity of the population at risk, is supported by health policy theory, and matches recommendations made in the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. 6 A targeted decision tree approach simplifies what is a highly complex problem and allows research findings to be more easily translated into policy.
Future empirical work focusing on the subgroups that comprise that population at risk of suicide and deliberate self harm is eagerly anticipated. It provides a basis on which evidence-based guidelines can be made available to practicing clinicians who can then be more confident about minimizing risk when assessing individual patients. Areas where knowledge is still awaited can be filled in temporarily by guidelines based on expert consensus, providing these have sufficient transparency and reliability. 37 With the publication of each new data set, established clinical guidelines can be continually revised and refined in the light of improved evidence on cost, effectiveness and costeffectiveness, with the potential to reconcile factors such as local acceptability, feasibility and resource availability.
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